Lineage director awarded 125,000 stock options
Lineage Cell Therapeutics director and 10% owner Neal C. Bradsher reported a grant of stock options covering 125,000 common shares.
Rhea-AI Filing Summary
Lineage Cell Therapeutics director and 10% owner Neal C. Bradsher reported a grant of stock options covering 125,000 common shares. The options have an exercise price of $1.30 per share and expire on July 1, 2036. They were granted on July 1, 2026 as director compensation under Lineage’s 2021 Equity Incentive Plan.
According to the filing, these options will vest and become exercisable on the earlier of July 1, 2027 or the company’s next annual shareholder meeting after the grant date, subject to his continuous service. The report also lists several existing option holdings with exercise prices between $0.8263 and $2.86 per share, expiring from 2029 through 2035.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 125,000 shares
Grant/Award
8 txns
Insider
Bradsher Neal C
Role
Director, 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | OPTION TO PURCHASE COMMON SHARES | 125,000 | $0.00 | $0.00 |
| holding | OPTION TO PURCHASE COMMON SHARES | -- | -- | -- |
| holding | OPTION TO PURCHASE COMMON SHARES | -- | -- | -- |
| holding | OPTION TO PURCHASE COMMON SHARES | -- | -- | -- |
| holding | OPTION TO PURCHASE COMMON SHARES | -- | -- | -- |
| holding | OPTION TO PURCHASE COMMON SHARES | -- | -- | -- |
| holding | OPTION TO PURCHASE COMMON SHARES | -- | -- | -- |
| holding | OPTION TO PURCHASE COMMON SHARES | -- | -- | -- |
Holdings After Transaction:
OPTION TO PURCHASE COMMON SHARES — 505,000 contracts for 380,000 underlying shares (Direct)
Footnotes (3)
- F1. These options will vest and become exercisable on the earlier of: (a) July 1, 2027 and (b) the date of Lineage Cell Therapeutics, Inc.'s (the "Issuer") next annual meeting of shareholders after the grant date, subject, in each case, to Neal C. Bradsher's (the "Reporting Person") continuous service with the Issuer.
- F2. These options were granted to the Reporting Person by the Issuer on July 1, 2026 as director compensation pursuant to the Issuer's 2021 Equity Incentive Plan, as amended.
- F3. These options are currently exercisable.
Key Figures
New option grant size: 125,000 options
New option exercise price: $1.30 per share
New option expiration: July 1, 2036
+4 more
7 metrics
New option grant size
125,000 options
Grant on July 1, 2026 as director compensation
New option exercise price
$1.30 per share
Exercise price for 125,000-share option grant
New option expiration
July 1, 2036
Expiration date of 125,000-share option grant
Existing option strike (low)
$0.8263 per share
Exercise price on 40,000 underlying shares, expiring July 1, 2030
Existing option strike (high)
$2.86 per share
Exercise price on 50,000 underlying shares, expiring July 1, 2031
Largest existing option block
75,000 underlying shares
Options with strike prices $0.9541 and $0.8977, expiring 2034–2035
New grant underlying shares
125,000 underlying shares
COMMON SHARES subject to 2036-expiring options
Key Terms
Equity Incentive Plan, director compensation, continuous service, exercisable, +1 more
5 terms
Equity Incentive Plan financial
"pursuant to the Issuer's 2021 Equity Incentive Plan, as amended."
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
director compensation financial
"These options were granted to the Reporting Person by the Issuer on July 1, 2026 as director compensation"
continuous service financial
"subject, in each case, to Neal C. Bradsher's continuous service with the Issuer."
exercisable financial
"These options will vest and become exercisable on the earlier of: (a) July 1, 2027"
underlying security financial
"underlying_security_title: "COMMON SHARES", underlying_security_shares"
FAQ
What did Neal C. Bradsher report in this Form 4 for LCTX?
Neal C. Bradsher reported receiving stock options for 125,000 Lineage Cell Therapeutics common shares. These options were granted as director compensation and are part of the company’s 2021 Equity Incentive Plan, reflecting ongoing equity-based compensation for his board service.
What are the key terms of Neal Bradsher’s new LCTX stock option grant?
The new options cover 125,000 common shares at an exercise price of $1.30 per share, expiring on July 1, 2036. They were granted on July 1, 2026 as director compensation under Lineage’s 2021 Equity Incentive Plan.
When do Neal Bradsher’s newly granted LCTX options vest and become exercisable?
The options will vest and become exercisable on the earlier of July 1, 2027 or the date of Lineage’s next annual meeting of shareholders after the grant date, provided Neal C. Bradsher maintains continuous service with the company.
Are all of Neal Bradsher’s reported LCTX options currently exercisable?
The filing states that certain options are currently exercisable, while the new 125,000-share grant is subject to future vesting. Existing positions include multiple option series with expirations from 2029 through 2035 and exercise prices between $0.8263 and $2.86 per share.
What other LCTX option positions does Neal Bradsher hold according to this report?
Neal C. Bradsher holds several existing options to purchase Lineage common shares, including tranches over 40,000, 50,000, 75,000 shares with exercise prices from $0.8263 to $2.86 per share and expirations between 2029 and 2035.
AI-generated analysis. How Rhea-AI works. Not financial advice.
